Table 3 |
||
|
Cervical test positivity rates for various clinical groups |
||
|
Cytological/histological diagnosis |
TERC positive cases [% (positive/total)] |
C-MYC positive cases [% (positive/total)] |
|
|
||
|
NILM-negative |
7.3 (8/109) |
19.3 (21/109) |
|
NILM-CIN1 |
0.0 (0/15) |
33.3 (5/15) |
|
NILM-CIN2+ |
37.5 (3/8) |
37.5 (3/8) |
|
ASCUS-negative |
12.8 (5/39) |
23.1 (9/39) |
|
ASCUS-CIN1 |
14.3 (1/7) |
14.3 (1/7) |
|
ASCUS-CIN2+ |
100.0 (4/4) |
75.0 (3/4) |
|
LSIL-negative |
18.2 (2/11) |
36.4 (4/11) |
|
LSIL-CIN1 |
75.0 (3/4) |
50.0 (2/4) |
|
LSIL-CIN2+ |
100.0 (6/6) |
100.0 (6/6) |
|
ASC-H-negative |
0.0 (0/3) |
0.0 (0/3) |
|
ASC-H -CIN1 |
0.0 (0/2) |
0.0 (0/2) |
|
ASC-H -CIN2+ |
100.0 (9/9) |
66.7 (6/9) |
|
HSIL-negative |
0.0 (0/2) |
0.0 (0/2) |
|
HSIL-CIN1 |
100.0 (1/1) |
100.0 (1/1) |
|
HSIL-CIN2+ |
100.0 (20/20) |
95.0 (19/20) |
|
SCC-CIN2+ |
100.0 (3/3) |
100.0 (3/3) |
|
|
||
|
Chen et al. Diagnostic Pathology 2012 7:40 doi:10.1186/1746-1596-7-40 |
||
